Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Tiziana Life Sciences says Accustem Sciences business will be spin out on Nasdaq

% of readers think this story is Fact. Add your two cents.

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it plans to list its diagnostics business Accustem Sciences on the Nasdaq stock market in the US after its demerger and the distribution of new stock to Tiziana shareholders.

“The board of directors of Accustem has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem’s business,” a short statement read.

Certainly, the American electronic market has become the natural home to ambitious, growing healthcare companies and has spawned some of the giants of the sector.

The understanding of what’s needed to develop a new drug or technology is such that Nasdaq-listed life sciences companies tend to trade at a premium valuation to similar businesses listed on this side of the Atlantic.

It also tends to be a more liquid market, and US-listed firms often have access to deeper pools of capital than their European counterparts. 


Accustem will own the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalised medicine business.

“Demerging the genomic risk assessment assay StemPrintER for breast cancer can enable the separate therapeutic and genomics entities to seek the most suitable independent funding or partnerships to move forwards and highlight the value of each segment as a ‘pure-play’,” Proactive analyst Emma Ulker said in a note on the company.

StemPrintER has been shown in a retrospective study to be superior to the standard assay acquired by Exact Sciences (NASDAQ:EXAS) as part of a US$2.8bn takeover deal.

The spin-out will allow Tiziana to focus solely on drug development. It advancing three candidates for a variety of indications in autoimmune disease, cancer and Covid.

Zacks call 

On Monday,  Zacks Small-Cap Research said US-quoted stock was worth US$7.50, more than double the closing share price.

It said the valuation was based on its probability adjusted estimates for successful phase III confirmatory trials in progressive Multiple Sclerosis (pMS) with nasally administered foralumab (the company’s lead candidate) and Crohn’s Disease (CD) with orally administered foralumab, which Zacks expects to yield registrational results in 2026.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.